Results: Circulating C19MC microRNAs were up-regulated (miR-517-5p, p= 0.005; miR-518b, p= 0.013; miR-520h, p= 0.021) or showed a trend toward up-regulation in patients destined to develop pre-eclampsia (miR-520a-5p, p= 0.067; miR-525-5p, p= 0.073). MiR-517-5p had the best predictive performance for pre-eclampsia with a sensitivity of 42.9%, a specificity of 86.2%, a PPV of 52.9% and a NPV of 80.6%. The combination of all examined circulating C19MC microRNAs had no advantage over using only the miR-517-5p biomarker to predict the occurrence of pre-eclampsia (a sensitivity of 20.6%, a specificity of 90.8%, a PPV of 44.8%, and a NPV of 76.0%). Conclusions: Up-regulation of miR-517-5p, miR-518b and miR-520h was associated with a risk of later development of pre-eclampsia. First trimester screening of extracellular miR-517-5p identified a proportion of women with subsequent pre-eclampsia. No circulating C19MC microRNA biomarkers were identified that could predict later occurrence of IUGR.
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Correlation between different methods for mean arterial pressure measurement and possible bias effects on early pre-eclampsia screening risks model Objectives: Pre-eclampsia (PE) is a condition that can cause vascular endothelial damage and vasospasms and is one of the maternal mortality causes. A.uterina dopplerometry investigation provides information about uteroplacental circulation. One of the pathological A.uterina dopplerometric indicators is considered A.uterina flow index (PI) > 95th centile, which is one of PE precursors. Our aim is to study whether the 1st trimester screening of A.uterina flow changes correlate with a genetic predisposition to PE. Methods: 28 included in a prospective randomised study participants conducted antenatal I trimester screening with A.uterina PI measurements and genes responsible for PE development were tested. The study group members had changed A.uterina flow, the control group A.uterina flow index was in normal range. Statistical data were analysed using SPSS data program. Results: In both study groups 100% of our subjects were homozygous F5 and F2 genes carriers. Control group's primiparous 25% were homozygous A/A and so even the G/G and 50% heterozygous for this gene, while the multiparas this group of representatives 14.3% were homozygous A/A, 28.6% G/G and 57.1% heterozygous A/G AGT gene. Analysing the same gene in the study population, 100% primiparous and 50% multiparous women were heterozygous A/G and 50% of multiparous were homozygous A/A. Primiparous of control group were 50% homozygous G/G and 50% homozygous A/A to MTHFR gene. 14.3% of control multiparous women were both homozygous G/G and A/A, but heterozygous in 71.4%. 14.3% of study primiparous were homozygous G/G, but 85.7% heterozygous, while multiparous were 100% homozygous -50% G/G and 50% A/A. Conclusions: Factor V Leiden and prothrombin mutation was homozygous for all of our study participants, so having an equal chance of developing PE. Primiparous who had normal A.uterina flow index was least likely to have AGT gene expression. Researching MTHR gene association with altered or normal A.uterina flow at 1st trimester was not found in any of the groups. 
